Another 3 emerging bispecific antibodies, TRAILR2-CDH17 (BI 905711) GCC-CD3 (PF-07062119) and CD137-PD-L1 (FS222), all showed potent T-cell mediated anti-tumor activity in CRC in preclinical trials 70-72. The gene discussed is CD274; the disease is neoplasm.